Charles J L la Porte1. 1. University of Ottawa, Ottawa Hospital Research Institute, Chronic Disease Program, Department of Medicine, 501 Smyth Road, mailbox 223, Ottawa, ON, K1H 8L6, Canada. claporte@ohri.ca
Abstract
BACKGROUND: The treatment of HIV infection underwent a major change in 1995 when saquinavir was the first protease inhibitor introduced into the market. This drug made the use of combination therapy in the treatment of HIV possible and increased the success rate of treatment. OBJECTIVE: This article will review recent literature on saquinavir to define its current role in HIV treatment, among the newer antiretroviral drugs. METHODS: Scientific literature and conference presentations were evaluated for relevant information pertaining to saquinavir. RESULTS/ CONCLUSIONS: Although underused, saquinavir has good efficacy and tolerability when compared to other protease inhibitors. The film-coated tablet formulation improved pill burden. Saquinavir still has potential in the treatment of adults, children and pregnant women.
BACKGROUND: The treatment of HIV infection underwent a major change in 1995 when saquinavir was the first protease inhibitor introduced into the market. This drug made the use of combination therapy in the treatment of HIV possible and increased the success rate of treatment. OBJECTIVE: This article will review recent literature on saquinavir to define its current role in HIV treatment, among the newer antiretroviral drugs. METHODS: Scientific literature and conference presentations were evaluated for relevant information pertaining to saquinavir. RESULTS/ CONCLUSIONS: Although underused, saquinavir has good efficacy and tolerability when compared to other protease inhibitors. The film-coated tablet formulation improved pill burden. Saquinavir still has potential in the treatment of adults, children and pregnant women.
Authors: Florian Rothweiler; Martin Michaelis; Peter Brauer; Jürgen Otte; Kristoffer Weber; Boris Fehse; Hans Wilhelm Doerr; Michael Wiese; Jörg Kreuter; Yousef Al-Abed; Ferdinando Nicoletti; Jindrich Cinatl Journal: Neoplasia Date: 2010-12 Impact factor: 5.715
Authors: Angélica Saraí Jiménez-Osorio; Sinaí Jaen-Vega; Eduardo Fernández-Martínez; María Araceli Ortíz-Rodríguez; María Fernanda Martínez-Salazar; Reyna Cristina Jiménez-Sánchez; Olga Rocío Flores-Chávez; Esther Ramírez-Moreno; José Arias-Rico; Felipe Arteaga-García; Diego Estrada-Luna Journal: Int J Mol Sci Date: 2022-05-17 Impact factor: 6.208